tbuckley/cabot-search huggingface dataset:
Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin administration and other clinical prognostic factors
Authors: E. Nugent, A. S. Case, I. Zighelboim, L. DeWitt, P. H. Thaker, L. S. Massad, M. A. Powell, D. G. Mutch, K. Trinkhaus, J. S. Rader
Journal: Journal of Clinical Oncology (2009)

e16525 Background: The standard treatment for locally advanced cervical cancer is combination weekly cisplatin and radiotherapy (RT). Toxicity and compliance issues often result in failure to complete the recommended six cycles of weekly chemotherapy. Our objective was to retrospectively evaluate the effect of number of chemotherapy cycles and other clinical and pathologic factors on progression-free (PFS) and overall survival (OS). Methods: Between January 2004 and May 2007 we identified 118 patients at our institution with locally advanced cervical cancer (stage 1B2-IVA) treated with combined weekly cisplatin (40 mg/m2) and RT from chemotherapy log records. PFS and OS were evaluated for associations with number of chemotherapy cycles as well as other clinical and pathologic factors. Kaplan-Meier and Cox proportional hazard models were utilized for statistical analyses. Results: The median age and BMI were 51 years (25–86) and 29.2 kg/m2 (15–69). The majority of patients had stage IB2 or II disease (70%), squamous histology (91%), and size &lt;6 cm (65%). Median RT duration was 50 days and 95% received brachytherapy. 30% of patients completed fewer than 6 cycles of chemotherapy and estimated PFS and OS were 63% and 75% respectively. 32 recurrences were detected with a median time to progression of 27 months. In multivariate analyses, number of chemotherapy cycles was independently predictive of PFS and OS. Patients that received &lt;6 cycles of cisplatin had a worse PFS (HR 2.65; 95%CI 1.35–5.17; p = 0.0045) and OS (HR 4.47; 95% CI 1.83–10.9; p = 0.001). Additionally, advanced stage, longer time to RT completion, and absence of brachytherapy were associated with decreased OS and PFS (p &lt; 0.05). Higher grade was associated with decreased PFS (p = 0.03) but not OS. Age, race, BMI, tumor size, smoking, histology, and IMRT were not statistically significant for OS or PFS. Conclusions: Number of cisplatin cycles, stage, grade, time to radiotherapy completion, and brachytherapy, are prognostic of PFS and OS in patients with cervical cancer undergoing treatment with combined cisplatin and RT. Efforts to decrease toxicity and improve compliance allowing for completion of six cycles of cisplatin may be associated with increased progression free and overall survival. No significant financial relationships to disclose.
Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis
Authors: K.F. Hjuler, L.C. Gormsen, M.H. Vendelbo, A. Egeberg, J. Nielsen, L. Iversen
Journal: British Journal of Dermatology (2016)

Psoriasis is associated with cardiovascular disease; it has been proposed that increased cardiovascular risk is caused by low‐grade systemic inflammation involving organs and tissues other than the skin and joints. To investigate signs of vascular inflammation in untreated patients with moderate‐to‐severe psoriasis assessed by 18F‐fluorodeoxyglucose (FDG) positron emission tomography‐computed tomography. A secondary objective was to assess signs of subcutaneous adipose tissue inflammation. This was an observational, controlled clinical study including patients with psoriasis (n = 12, mean ± SD age 61·4 ± 4·1 years, 83% men, mean ± SD Psoriasis Area Severity Index score 14·5 ± 4·3) and matched controls (n = 23, mean ± SD age 60·4 ± 4·5 years, 87% men). Vascular inflammation was measured using aortic maximal standardized uptake values (SUVmax) and the target‐to‐background ratio (TBRmax) of the whole vessel and aortic segments. Subcutaneous adipose tissue inflammation was assessed and compared with regard to SUVmax and TBRmax. Arterial inflammation was increased in patients with psoriasis vs. controls (mean ± SD whole vessel TBRmax 2·46 ± 0·31 vs. 2·09 ± 0·36; P = 0·005). In patients with psoriasis, higher FDG uptake values were observed for all aortic segments except the ascending aorta. Subcutaneous adipose tissue FDG uptake was increased in patients with psoriasis vs. controls (mean ± SD TBRmax 0·49 ± 0·18 vs. 0·31 ± 0·12; P = 0·002). Associations remained significant after adjusting for body mass index and age. Global arterial inflammation and subcutaneous inflammation were significantly increased in patients with moderate‐to‐severe psoriasis compared with controls.
The Role of Akt-Forkhead Signaling in the Hematopoietic Stem-Progenitor Cell Differentiation: Expansion of Hematopoietic and Endothelial Progenitors from Akt-1 Null Marrows and Peripheral Blood Involving FKHRL1-Activation.
Authors: Masaki Mogi, Kenneth Walsh, Tetsuro Miki
Journal: Blood (2004)
TCT-258 Clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention for multi-vessel coronary artery disease
Authors: Min Soo Cho, Do-yoon Kang, Ungjeong Do, Jung Ae Hong, Osung Kwon, Cheol Hyun Lee, JAESEOK BAE, Yu Na Kim, Se Hun Kang, Sung-Han Yoon, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2016)
Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: A French Reference Center for PIDs (CEREDIH) study
Authors: Vincent Barlogis, Nizar Mahlaoui, Pascal Auquier, Isabelle Pellier, Fanny Fouyssac, Camille Vercasson, Maya Allouche, Carolina Brito De Azevedo, Felipe Suarez, Despina Moshous, Bénédicte Neven, Marlène Pasquet, Eric Jeziorski, Nathalie Aladjidi, Nicolas Schleinitz, Caroline Thomas, Virginie Gandemer, Françoise Mazingue, Patrick Lutz, Olivier Hermine, Capucine Picard, Stéphane Blanche, Gérard Michel, Alain Fischer
Journal: Journal of Allergy and Clinical Immunology (2016)
TCT-311 Everolimus- Versus Zotarolimus-Eluting Stent Following Percutaneous Coronary Chronic Total Occlusion Intervention
Authors: Min Soo Cho, Do-yoon Kang, Ungjeong Do, Jung Ae Hong, Kyusup Lee, Osung Kwon, JAESEOK BAE, Yu Na Kim, Cheol Hyun Lee, Se Hun Kang, Sung-Han Yoon, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2016)
TCT-708 Safety and Efficacy of the Percutaneous Transaxillary Access for Transcatheter Aortic Valve Implantation using various Transcatheter Heart Valves in 100 Consecutive Patients
Authors: Ulrich Schafer, Florian Deuschl, Niklas Schofer, Christian Frerker, Daniel Reichart, Johannes Schirmer, Tobias Schmidt, Karl-Heinz Kuck, Felix Kreidel, Izamu Mizote, Hermann Reichenspurner, Stefan Blankenberg, Lenard Conradi
Journal: Journal of the American College of Cardiology (2016)
Economic opportunity, health behaviours, and health outcomes in the USA: a population-based cross-sectional study
Authors: Atheendar S Venkataramani, Rachel Brigell, Rourke O'Brien, Paula Chatterjee, Ichiro Kawachi, Alexander C Tsai
Journal: The Lancet Public Health (2016)

BackgroundInequality of opportunity, defined as differences in the prospects for upward social mobility, might have important consequences for health. Diminished opportunity can lower the motivation to invest in future health by reducing economic returns to health investments and undermining hope. We estimated the association between county-level economic opportunity and individual-level health in young adults in the general US population.MethodsIn this population-based cross-sectional study, we used individual-level data from the 2009–12 United States Behavioral Risk Factor Surveillance Surveys. Our primary outcomes were current self-reported overall health and the number of days of poor physical and mental health in the last month. Economic opportunity was measured by the county-averaged national income rank attained by individuals born to families in the lowest income quartile. We restricted our sample to adults aged 25–35 years old to match the data used to assign exposure. Multivariable ordinary least squares and probit models were used to estimate the association between the outcomes and economic opportunity. We adjusted for a range of demographic and socioeconomic characteristics, including age, sex, race, education, income, access to health care, area income inequality, segregation, and social capital.FindingsWe assessed nearly 147 000 individuals between the ages of 25 years and 35 years surveyed from 2009 to 2012. In models adjusting for individual-level demographics and county-level socioeconomic characteristics, increases in county-level economic opportunity were associated with greater self-reported overall health. An interdecile increase in economic opportunity was associated with 0·76 fewer days of poor mental health (95% CI −1·26 to −0·25) and 0·53 fewer days of poor physical health (−0·96 to −0·09) in the last month. The results were robust to sensitivity analyses.InterpretationEconomic opportunity is independently associated with self-reported health and health behaviours. Policies seeking to expand economic opportunities might have important spillover effects on health.FundingRobert Wood Johnson Foundation Health and Society Scholars Program.
Thymic Shielding (TS) in Recipients of Total Body Irradiation (TBI) and Alternative Donor Hematopoietic Stem Cell Transplant (AD-HSCT): Reduced Risk of Opportunistic Infection in Patients with Fanconi Anemia (FA).
Authors: Margaret L. MacMillan, Bruce R. Blazar, Todd E. DeFor, Kathryn Dusenbery, John E. Wagner
Journal: Blood (2006)
Valuation of MIP-1α and MR-Proadm in Serum of Patients with Systemic AL Amyloidosis
Authors: Giusy Antolino, Alessandro Moscetti, Federica Resci, Daniela De Benedittis, Virginia Naso, Maria Paola Bianchi, Francescaromana Festuccia, Gerardo Salerno, Maria Teresa Corsetti, Patrizia Cardelli, Giovanna Ferranti, Giacinto La Verde
Journal: Blood (2012)
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome
Authors: Caroline H Shiboski, Stephen C Shiboski, Raphaèle Seror, Lindsey A Criswell, Marc Labetoulle, Thomas M Lietman, Astrid Rasmussen, Hal Scofield, Claudio Vitali, Simon J Bowman, Xavier Mariette
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To develop and validate an international set of classification criteria for primary Sjögren9s syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These criteria were developed for use in individuals with signs and/or symptoms suggestive of SS. <h3>Methods</h3> We assigned preliminary importance weights to a consensus list of candidate criteria items, using multi-criteria decision analysis. We tested and adapted the resulting draft criteria using existing cohort data on primary SS cases and non-SS controls, with case/non-case status derived from expert clinical judgement. We then validated the performance of the classification criteria in a separate cohort of patients. <h3>Results</h3> The final classification criteria are based on the weighted sum of five items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm<sup>2</sup>, each scoring 3; an abnormal Ocular Staining Score of ≥5 (or van Bijsterveld score of ≥4), a Schirmer9s test result of ≤5 mm/5 min and an unstimulated salivary flow rate of ≤0.1 mL/min, each scoring 1. Individuals with signs and/or symptoms suggestive of SS who have a total score of ≥4 for the above items meet the criteria for primary SS. Sensitivity and specificity against clinician-expert—derived case/non-case status in the final validation cohort were high, that is, 96% (95% CI92% to 98%) and 95% (95% CI 92% to 97%), respectively. <h3>Conclusion</h3> Using methodology consistent with other recent ACR/EULAR-approved classification criteria, we developed a single set of data-driven consensus classification criteria for primary SS, which performed well in validation analyses and are well suited as criteria for enrolment in clinical trials.
TCT-752 Transcatheter Aortic Valve Replacement in Patients with Previous Mitral Surgery – A Multicentre Study
Authors: Ignacio Amat-Santos, Carlos Cortes, Antonio Munoz, Jose Suarez De Lezo, Luis Nombela-Franco, Enrique Gutiérrez, Raul Moreno, Vicente Serra, Jose M. de la Torre Hernandez, Javier Castrodeza, Javier Tobar, Jose A. San Roman
Journal: Journal of the American College of Cardiology (2016)
Effect of Graft and Early Posttransplantation Invariant Natural Killer T Cells on Disease Relapse Post Allogeneic Hematopoeitic Cell Transplantation
Authors: Sauvi chang-Fong, Kristin Rathmann, Julie Pepe, Yasser Khaled, Alicja J Copik, Jeremiah Oyer, Melhem M. Solh
Journal: Blood (2014)
A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
Authors: Fausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, Antonio Spitaleri, Gabriele Gugliotta, Francesco Fabbiano, Isabella Capodanno, Donato Mannina, Marzia Salvucci, Agostino Antolino, Roberto Marasca, Maurizio Musso, Monica Crugnola, Stefana Impera, Elena Trabacchi, Caterina Musolino, Francesco Cavazzini, Giuseppe Mineo, Patrizia Tosi, Carmela Tomaselli, Michele Rizzo, Sergio Siragusa, Miriam Fogli, Riccardo Ragionieri, Alessandro Zironi, Simona Soverini, Giovanni Martinelli, Michele Cavo, Paolo Vigneri, Fabio Stagno, Gianantonio Rosti, Michele Baccarani
Journal: American Journal of Hematology (2016)

Chronic myeloid leukemia (CML) treatment is based on company-sponsored and academic trials testing different tyrosine kinase inhibitors (TKIs) as first-line therapy. These studies included patients selected according to many inclusion-exclusion criteria, particularly age and comorbidities, with specific treatment obligations. In daily clinical practice (real-life), inclusion-exclusion criteria do not exist, and the treatment outcome does not only depend on the choice of first-line TKI but also on second- and third-line TKIs. To investigate in a real-life setting the response and the outcome on first-line imatinib, with switch to second generation TKIs in case of unsatisfying response or intolerance, we analyzed all newly diagnosed patients (N = 236), living in two Italian regions, registered in a prospective study according to population-based criteria and treated front-line with imatinib. A switch from imatinib to second-generation TKIs was reported in 14% of patients for side effects and in 24% for failure or suboptimal response, with an improvement of molecular response in 57% of them. The 5-year overall survival (OS) and leukemia-related survival (LRS) were 85% and 93%, respectively; the 4-year rates of MR3.0 and MR4.0 were 75% and 48%, respectively. Cardiovascular complications were reported in 4% of patients treated with imatinib alone and in 6% of patients receiving nilotinib as second-line. Older age (≥70 years) affected OS, but not LRS. These data provide an unbiased reference on the CML management and on the results of TKI treatment in real-life, according to ELN recommendations, using imatinib as first-line treatment and second-generation TKIs as second-line therapy. Am. J. Hematol. 92:82-87, 2017. © 2016 Wiley Periodicals, Inc.
TCT-353 Underweight Status, Platelet Reactivity, and 2-Year Clinical Outcomes in Patients Undergoing PCI With DES: An ADAPT-DES Study Analysis
Authors: Puja Parikh, Ajay Kirtane, Giora Weisz, Thomas Stuckey, M. Ozgu Ozan, Bernhard Witzenbichler, Michael Rinaldi, Franz-Josef Neumann, D. Christopher Metzger, Timothy Henry, David Cox, Peter L. Duffy, Bruce Brodie, Ernest Mazzaferri, Roxana Mehran, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
TCT-318 Ten-year All-cause Mortality after Simple versus Complex Stenting of Coronary Artery Bifurcation Lesions in the Randomized Nordic Bifurcation Study
Authors: Terje Steigen, Niels Holm, Indulis Kumsars, Matti Niemela, Stefan James, Andrejs Erglis, Kari Kervinen, Jan Skov Jensen, Anders Michael Galloe, Rune Wiseth, Paul Gunnes, Oliver Meyerdierks, Svein Rotevatn, Saila Vikman, Michael Maeng, Jan Ravkilde, Antti Ylitalo, Steffen Helqvist, Iwar Sjogren, Lisette Okkels Jensen, Mika Laine, Juha Hartikainen, Juhani Airaksinen, Jens Flensted Lassen, Leif Thuesen, Evald Christiansen
Journal: Journal of the American College of Cardiology (2016)
Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC)
Authors: S. M. Gadgeel, A. Wozniak, M. J. Edelman, M. Valdivieso, L. Heilbrun, R. Venkatramanamoorthy, A. Shields, P. LoRusso, D. Hackstock, J. Ruckdeschel
Journal: Journal of Clinical Oncology (2009)

e19007 Background: There are only limited data regarding the use of anti-VEGF therapy in recurrent NSCLC and no data in NSCLC pts previously treated with bevacizumab. We are currently conducting a phase II trial evaluating cediranib, an oral inhibitor of VEGFR 1,2 and 3, and pemetrexed in recurrent NSCLC pts who may or may not have previously received bevacizumab. Methods: Pts with progressive and measurable NSCLC, 1 or 2 prior regimens, PS0–2, all histologic sub-types, BP ≤ 140/90, treated brain metastases are eligible. Pts on anti-coagulants are allowed. Pts with hemorrhage within 4 weeks are excluded. Pts start on cediranib 30mg daily followed 7 days later by pemetrexed at 500 mg/m 2 every 21 days and cediranib daily. The study consists of two cohorts- cohort A (no prior bevacizumab) and cohort B (prior bevacizumab). Planned accrual is 37 pts each cohort. Consenting pts will undergo FLT PET scans and blood draw for circulating tumor cells before therapy, 1 week after cediranib, and after 1 cycle of the combination. Results: 33 pts have started therapy, (Cohort A- 20, Cohort B- 13), median age- 60, males- 56%, ever smokers- 88%, adenocarcinoma- 64%, squamous- 12%, brain mets- 27%, 1 prior regimen- 52%, PS0–1- 88%. Median cycles- 4 (range- 0–15). Grade 3/4 toxicities- neutropenia- 7pts, febrile neutropenia- 1pt, fatigue-7pts, diarrhea- 3pts, hypertension- 1pt, anorexia- 2pts, cardiac ischemia- 1pt, bronchopleural fistula- 1pt, esophagitis- 1pt. No major hemorrhage. Of the 17 pts who received cediranib for ≥ 4 cycles, 71% required dose reduction and of the 18 pts who received pemetrexed for ≥ 4 cycles, 22% required dose reduction. 31 pts (Cohort A- 19, Cohort B- 12) are response evaluable. Confirmed response rate is 16%(90% CI- 0.08–0.30) (Cohort A- 10%, Cohort B- 25%) and disease control rate (response+stable disease) is 71% (90% CI-0.56–0.82) (Cohort A- 74%, Cohort B- 67%). 8 of 9 pts who had FLT PET scans had a 20% or greater decline in standard uptake value after 1 week of cediranib alone. Conclusions: Cediranib and pemetrexed combination is tolerable. Efficacy has been observed with the combination in recurrent NSCLC pts, including those previously treated with bevacizumab. Accrual to this trial is ongoing. [Table: see text]
UTILIDAD DE LA COLOCACIÓN DE PRÓTESIS PREVIA A QUIMIOTERAPIA EN PACIENTES CON TUMORES ESTENOSANTES DE RECTO Y COLON IZQUIERDO ESTADIO IV: ESTUDIO RETROSPECTIVO
Authors: J Carrascosa Gil, FJ Suárez Alecha, G Marín, F Oteiza Martínez, B Oronoz Martínez, JF Juanmartiñena Fernández, M Rullán Iriarte, L Casanova Ortiz, A Pueyo Royo, JJ Vila Costas
Journal: Endoscopy (2016)

La colocación de prótesis metálicas autoexpandibles (PMA) previa a la quimioterapia en pacientes asintomáticos con tumores del lado izquierdo irresecables o metastásicos es controvertida, incluso desaconsejándose en una guía europea.
TCT-126 Simultaneous, not Staged, Deployment of Biventricular Micro-Axial Flow Impella Catheters (BiPella) is Associated with Improved Survival for Cardiogenic Shock Involving Biventricular Failure
Authors: Navin Kapur, Catalina Breton, Ryan O'Kelly, Michele Esposito, Andrew Mullin, Shiva Annamalai, Mark Grise, Michael Kiernan, Duc Thinh Pham, Mark Anderson, D. Lynn Morris
Journal: Journal of the American College of Cardiology (2016)
P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC
Authors: Stephen Liu, Martin Reck, Tony Mok, Melissa Johnson, Xiongwen Tang, Sivuonthanh Lam, Daniel Waterkamp, Ariel Lopez-Chavez, Alan Sandler, Giuseppe Giacconne, Leora Horn
Journal: Journal of Thoracic Oncology (2017)
Elevated Peripheral Blood (PB) Cytomegalovirus (CMV) Viral Loads and Reduced CD8+ T-Cell Counts Are Common Findings in T-Cell Lymphoma before Initiation of Therapy.
Authors: Grady Terrence, Nelson Melissa, Staub Annette, Tucker Maria, Baiocchi Robert, Nuovo Gerard, Magro Cynthia, Porcu Pierluigi
Journal: Blood (2005)
TCT-385 The role of Neutrophil Gelatinase-Associated Lipocalin (NGAL) for evaluation of kidney function in patients undergoing coronary angiography
Authors: Iliyana Petrova, Hristo Mateev, Alexander Alexandrov, George Vladimirov, Alexandra Bankova, Dobrin Vassilev, Iva Paskaleva, Nina Gotcheva, Valery Gelev
Journal: Journal of the American College of Cardiology (2016)
Clinical Usefulness of Long-Term Oxygen Therapy in Adults
Authors: Magnus Ekström
Journal: New England Journal of Medicine (2016)

The fact that we all need oxygen to survive might make the benefit of supplemental oxygen in hypoxemia seem obvious. It is not. Long-term oxygen therapy was the first treatment to improve prognosis in patients with chronic obstructive pulmonary disease (COPD) and chronic severe hypoxemia.1,2 However, the question of whether long-term oxygen therapy is beneficial in moderate hypoxemia has been floating in the air.The literature on the efficacy of long-term oxygen therapy requires no librarian. The current indications for its use are based on two unblinded, randomized trials that were conducted in the 1970s and involved a total . . .
TCT-835 Endothelial Function Assessed by Expression of Adherens Junctions and Inflammation between Durable and Biodegradable Polymer Drug-Eluting Stents in the Rabbit Iliofemoral Model
Authors: Kazuyuki Yahagi, Frank Kolodgie, Qi Cheng, Eduardo Acampado, Liang Guo, Hiroyoshi Mori, Sho Torii, Maria Romero, Laura Perkins, Aloke Finn, Renu Virmani
Journal: Journal of the American College of Cardiology (2016)
Meditation and Medication—What About a Middle Path?
Authors: David A. Lovas, Jacqueline Lutz, Zev Schuman-Olivier
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
TCT-323 Predictors of clinical outcome and subsequent target lesion revascularization after percutaneous coronary procedures with drug eluting stents and everolimus eluting bioresorbable scaffolds for cardiac allograft vasculopathy
Authors: Valentina Vaccaro, Irene Maria Bossi, Margherita D'Anna, Giacomo Piccalo, Maria Paola Caria, Giovanna Pedrazzini, Enrico Ammirati, Fabio Turazza, Fabrizio Oliva
Journal: Journal of the American College of Cardiology (2016)